Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug-Induced Movement Disorder Clear all
Recruiting Phase 2 Interventional

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

NCT07365462
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-1065890, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Bryant, Arkansas • Chino, California • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 24, 2026, 4:29 AM EDT
Enrolling by invitation Phase 1 Interventional

Phase 1/2a Study of ANPD001 in Parkinson Disease

NCT06344026
View directory record Official record
Conditions
Parkinson Disease
Interventions
ANPD001, Custom Device
Biological · Device
Lead sponsor
Aspen Neuroscience
Industry
Eligibility
40 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 24, 2026, 4:29 AM EDT
Completed No phase listed Observational

The Assessment of Movement Disorders Utilizing Live Two-Way Video

NCT01467089
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
Two way video assessment
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Jul 24, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2009 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia

NCT03287778
View directory record Official record
Conditions
Tardive Dyskinesia, Antipsychotic Agents
Interventions
Pyridoxine, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 4 Interventional Results available

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

NCT03891862
View directory record Official record
Conditions
Tardive Dyskinesia (TD)
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

NCT01688037
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
49
States / cities
Little Rock, Arkansas • Anaheim, California • Carson, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

NCT02198794
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
SD-809, Placebo
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
44
States / cities
Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Jul 24, 2026, 4:29 AM EDT
Completed No phase listed Observational Results available

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

NCT04064294
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced
Interventions
Intravenous Infusion
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 24, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation

NCT00065286
View directory record Official record
Conditions
Akathisia
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1999
U.S. locations
2
States / cities
Morganton, North Carolina • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Heart Rate Variability in Response to Metformin Challenge

NCT02500628
View directory record Official record
Conditions
Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
Interventions
Metformin
Drug
Lead sponsor
Woodinville Psychiatric Associates
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Woodinville, Washington
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

NCT01092065
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AFQ056 with L-dopa, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jul 24, 2026, 4:29 AM EDT
Withdrawn Phase 2 Interventional

A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia

NCT02064010
View directory record Official record
Conditions
Drug-induced Tardive Dyskinesia
Interventions
SNC-102, Placebo
Drug
Lead sponsor
Synchroneuron Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Jul 24, 2026, 4:29 AM EDT
Not listed Phase 2 Interventional

Improving Hand Use in Multiple Sclerosis

NCT01081275
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
CI Therapy, CAM treatments
Behavioral
Lead sponsor
National Multiple Sclerosis Society
Other
Eligibility
21 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Addressing Involuntary Movements in Tardive Dyskinesia

NCT02291861
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
SD-809, Placebo
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
53
States / cities
Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 24, 2026, 4:29 AM EDT
Not listed No phase listed Observational

Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism

NCT02361255
View directory record Official record
Conditions
Secondary Parkinsonism, Parkinson's Disease
Interventions
no intervention
Other
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
40 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 24, 2026, 4:29 AM EDT
Not listed Not applicable Interventional

Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

NCT06011408
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
TDtect
Other
Lead sponsor
iRxReminder
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Brooklyn, New York • Garfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT01474421
View directory record Official record
Conditions
Dyskinesias, Drug-induced
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 85 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Sacramento, California • Manhasset, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01393600
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • National City, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 3 Interventional

Levetiracetam Treatment of Tardive Dyskinesia

NCT00291213
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
levetiracetam, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 24, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

NCT02405091
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Anaheim, California • Glendale, California • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Jul 24, 2026, 4:29 AM EDT
Withdrawn Phase 4 Interventional

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

NCT06107829
View directory record Official record
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions
Valbenazine Oral Capsule
Drug
Lead sponsor
Stephen Ruedrich
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 24, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers

NCT00001771
View directory record Official record
Conditions
Healthy, Mental Disorder, Obsessive Compulsive Disorder, Schizophrenia, Tourette Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 4:29 AM EDT